Seller record · Telehealth service

welludr.

By Peptide Alliance, Editorial publisherRecorded October 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S3, pharmacy identification: The FAQ tells patients to read the pharmacy name on their prescription label or ask the care team; home, FAQ, contact and privacy pages examined do not name a dispensing pharmacy. 2 more criteria also fail; see the table below.

At a glance

welludr.Telehealth service

4/8criteria passed

Price: Not printed before a consultation or sign-up
Sells: compounded semaglutide, compounded tirzepatide
FDA letters: None on file

Visit welludr.See all eight dispositions

Telehealth service. Passes 4 of 8 criteria. 1 not verified, counting neither way. Recorded against Standard v1.1.

A telehealth platform offering compounded semaglutide and tirzepatide through OpenLoop clinicians. The storefront identifies itself as welludr. and directs patients to their prescription label for the dispensing pharmacy.

Operating entity Welludr LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	welludr.'s FAQ
S2	Prescription gating	NOT VERIFIED	welludr.'s website
S3	Pharmacy identification	FAIL	welludr.'s FAQ
S4	Compounding disclosure	PASS	welludr.'s website
S5	Analytical documentation	FAIL	welludr.'s website
S6	Business address	PASS	welludr.'s privacy notice for California residents page
S7	Price disclosure	FAIL	welludr.'s website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSPublic medical disclosure identifies OpenLoop Health and other U.S.-licensed clinician networks, whose clinicians review medical history and make independent prescribing decisions.Source: welludr.'s FAQ.

S2NOT VERIFIEDThe public payment-versus-questionnaire sequence did not resolve, because the homepage says payment precedes clinical review but does not establish whether the medical-history questionnaire must be completed before payment. The check is open.Source: welludr.'s website.

S3FAILThe FAQ tells patients to read the pharmacy name on their prescription label or ask the care team; home, FAQ, contact and privacy pages examined do not name a dispensing pharmacy.Source: welludr.'s FAQ.

S4PASSThe homepage labels semaglutide and tirzepatide as compounded and states these preparations are not FDA-approved, FDA-approved generics or evaluated by FDA before marketing.Source: welludr.'s website.

S5FAILNo certificate of analysis or lot document is published on the home, FAQ, contact or privacy pages.Source: welludr.'s website.

S6PASSThe California privacy notice identifies Welludr LLC at 7901 4th Street North, Suite 300, St. Petersburg, FL 33702.Source: welludr.'s privacy notice for California residents page.

S7FAILThe home, FAQ and contact pages examined do not publish a medication program price. Payment terms refer to the price shown before payment.Source: welludr.'s website.

S8PASSNo FDA warning letter names Welludr, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit welludr.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.